EpiToMi Medical Aims for $50 Million in Sales with New Direct-to-Consumer Strategy

EpiToMi Medical, a company whose stock has recently experienced significant volatility, is shifting its strategy under new CEO Dr. Dovl Rephaeli to focus on direct-to-consumer sales in the U.S. market. Rephaeli, grandson of former Israeli Prime Minister Levi Eshkol, believes the company's previous issues stemmed from its distribution model rather than its product, a capsule designed for weight loss.

Rephaeli, who has extensive experience in building and marketing medical products directly to consumers in the U.S., aims to leverage the growing market for weight management solutions. He points to the success of GLP-1 drugs, which have educated consumers about medical treatments for obesity, creating a fertile ground for EpiToMi's product. He argues that while GLP-1 drugs offer significant weight loss, they come with substantial side effects and a high discontinuation rate, creating an opportunity for EpiToMi's non-systemic, prescription medical device.

The company received FDA approval for its capsule, which works by absorbing stomach fluid to induce a feeling of fullness. Rephaeli contrasts this with GLP-1 drugs, highlighting EpiToMi's favorable safety profile and lack of systemic absorption. He plans to build a direct-to-consumer (DTC) and telehealth infrastructure in the U.S., emphasizing that the company will retain customer relationships, unlike previous models relying on distributors.

EpiToMi previously faced regulatory scrutiny, with the Israel Securities Authority fining the company and its former executives NIS 1.85 million for misleading reports in 2023. Despite this, the stock saw a recent surge, which Rephaeli attributes to the strategic shift and the company's undervalued position. He acknowledges the need for future capital to fund the U.S. market entry, but emphasizes a lean, performance-based approach to investment.

Rephaeli also clarified the role of co-founder and Chairman Shimon Akehuz, stating he remains actively involved in strategic decisions. The company's manufacturing capacity in Israel is modular and scalable, designed to meet projected demand without requiring massive upfront capital expenditure. Rephaeli believes EpiToMi's unique combination of FDA approval, a non-systemic mechanism, and a competitive price point positions it well in a market shaped by the success and limitations of competitors.